Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: severe acute respiratory syndrome-coronavirus 3CL protease inhibitors - Microbial Novoteqs

Drug Profile

Research programme: severe acute respiratory syndrome-coronavirus 3CL protease inhibitors - Microbial Novoteqs

Latest Information Update: 11 Jul 2016

At a glance

  • Originator Microbial Novoteqs
  • Class Antivirals
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Severe acute respiratory syndrome

Most Recent Events

  • 11 Jul 2016 Early research in Severe acute respiratory syndrome in USA (unspecified route)

Development Overview

Introduction

Microbial Novoteqs is developing severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors for the treatment of SARS. The company has received $US1.7 million in grants and additional subcontracts from the National Institutes of Health (NIH) to partly pursue high-throughput screening for inhibitors of viral agents that pose global health threats. According to the company pipeline, as of July 2016, development is at the hit-to-lead stage in the US.

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals
  • Target Peptide hydrolase
  • Mechanism of Action Peptide hydrolase inhibitors
  • WHO ATC code

    J05A-E (Protease inhibitors)

  • EPhMRA code

    J5B5 (Respiratory antivirals excluding influenza products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Severe acute respiratory syndrome - - Research USA unspecified / unspecified Microbial Novoteqs 11 Jul 2016

Commercial Information

Involved Organisations

Organisation Involvement Countries
Microbial Novoteqs Originator USA
Microbial Novoteqs Owner USA
National Institutes of Health (USA) Funder USA

Development History

Event Date Update Type Comment
11 Jul 2016 Phase Change Early research in Severe acute respiratory syndrome in USA (unspecified route) Updated 11 Jul 2016
Back to top